Treatment of Active Tuberculosis in HIV-Coinfected Patients: A Systematic Review and Meta-Analysis

被引:119
作者
Khan, Faiz A. [1 ]
Minion, Jessica [1 ]
Pai, Madhukar [1 ,2 ]
Royce, Sarah [3 ]
Burman, William [4 ]
Harries, Anthony D. [5 ,6 ]
Menzies, Dick [1 ]
机构
[1] McGill Univ, Ctr Hlth, Montreal Chest Inst, Montreal, PQ H2X 2P4, Canada
[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H2X 2P4, Canada
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Denver Publ Hlth, Denver, CO USA
[5] Int Union TB & Lung Dis, Paris, France
[6] London Sch Hyg & Trop Med, London WC1, England
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; SHORT-COURSE CHEMOTHERAPY; RIO-DE-JANEIRO; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; PULMONARY TUBERCULOSIS; RECURRENT TUBERCULOSIS; CLINICAL PRESENTATION; TREATMENT OUTCOMES;
D O I
10.1086/651686
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse. Methods. A systematic review and meta-analysis of randomized, controlled trials and cohort studies was conducted to evaluate the impact of duration and dosing schedule of rifamycin and use of antiretroviral therapy in the treatment of active tuberculosis in HIV-positive patients. In included studies, the initial tuberculosis diagnosis, failure, and/or relapse were microbiologically confirmed, and patients received standardized rifampin-or rifabutin-containing regimens. Pooled cumulative incidence of treatment failure, death during treatment, and relapse were calculated using random-effects models. Multivariable meta-regression was performed using negative binomial regression. Results. After screening 5158 citations, 6 randomized trials and 21 cohort studies were included. Relapse was more common with regimens using 2 months rifamycin (adjusted risk ratio, 3.6; 95% confidence interval, 1.1-11.7) than with regimens using rifamycin for at least 8 months. Compared with daily therapy in the initial phase (patients from 35 study arms), n = 3352 thrice-weekly therapy (n = 211 patients from 5 study arms) was associated with higher rates of failure (adjusted risk ratio, 4.0; 95% confidence interval, 1.5-10.4) and relapse [adjusted risk ratio, 4.8; 95% confidence interval, 1.8-12.8). There were trends toward higher relapse rates if rifamycins were used for only 6 months, compared with >= 8 months, or if antiretroviral therapy was not used. Conclusions. This review raises serious concerns regarding current recommendations for treatment of HIV-tuberculosis coinfection. The data suggest that at least 8 months duration of rifamycin therapy, initial daily dosing, and concurrent antiretroviral therapy might be associated with better outcomes, but adequately powered randomized trials are urgently needed to confirm this.
引用
收藏
页码:1288 / 1299
页数:12
相关论文
共 68 条
[1]   RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE [J].
ACKAH, AN ;
COULIBALY, D ;
DIGBEU, H ;
DIALLO, K ;
VETTER, KM ;
COULIBALY, IM ;
GREENBERG, AE ;
DECOCK, KM .
LANCET, 1995, 345 (8950) :607-610
[2]   Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand [J].
Akksilp, Somsak ;
Karnkawinpong, Opart ;
Wattanaamornkiat, Wanpen ;
Viriyakitja, Daranee ;
Monkongdee, Patarna ;
Sitti, Walya ;
Rienthong, Dhanida ;
Siraprapasiri, Taweesap ;
Wells, Charles D. ;
Tappero, Jordan W. ;
Varma, Jay K. .
EMERGING INFECTIOUS DISEASES, 2007, 13 (07) :1001-1007
[3]  
[Anonymous], 2004, Treatment of tuberculosis: guidelines for national programmes
[4]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[5]  
*CECP, 2003, MMWR RECOMM REP, V52
[6]   Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection [J].
Chaisson, RE ;
Clermont, HC ;
Holt, EA ;
Cantave, M ;
Johnson, MP ;
Atkinson, J ;
Davis, H ;
Boulos, R ;
Quinn, TC ;
Halsey, NA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (04) :1034-1038
[7]  
Colmenero J D, 1997, Enferm Infecc Microbiol Clin, V15, P129
[8]  
Daniel O J, 2006, Niger J Med, V15, P222
[9]   Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? [J].
Dlodlo, RA ;
Fujiwara, PI ;
Enarson, DA .
EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (04) :751-757
[10]  
Domoua K, 1998, B SOC PATHOL EXOT, V91, P312